Pantoprazol Azevedos (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazol Azevedos, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders in adults and children. GNH USA supplies Pantoprazol Azevedos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Azevedos is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of the oesophageal lining. - Erosive esophagitis: accelerates healing of erosions caused by acid exposure. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumours. - Peptic ulcer disease (duoden‑and gastric ulcer): supports ulcer healing and reduces recurrence.

Pantoprazol Azevedos may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools, usually transient. - Nausea: occasional feeling of queasiness. - Abdominal pain: cramp‑like discomfort. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhoea. - Acute interstitial nephritis: kidney inflammation with reduced urine output. - Severe hypersensitivity: rash, angio‑edema or anaphylaxis. - Osteoporotic fractures: increased risk with long‑term use. - Low magnesium (hypomagnesemia): muscle cramps, tremor, cardiac arrhythmia. - Liver enzyme elevation: asymptomatic rise in ALT/AST.

When prescribing Pantoprazol Azevedos, clinicians should consider several safety aspects: - Assess renal function: dose adjustment may be needed in severe impairment. - Review concomitant medications: potential for altered absorption of drugs requiring acidic pH. - Monitor long‑term therapy: evaluate need for continuation after 8‑12 weeks. - Pregnancy and lactation: use only if clearly indicated, weighing maternal benefits against potential risks. - Elderly patients: start at the lowest effective dose and monitor for fractures. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines. Awareness of the interaction potential helps optimise therapy.

Major Interactions (Avoid): - Antifungal azoles (ketoconazole, itraconazole): reduced absorption and loss of efficacy. - HIV protease inhibitors (ritonavir, atazanavir): decreased plasma concentrations.

Moderate Interactions (Monitor Closely): - Clopidogrel: diminished antiplatelet effect, consider alternative antiplatelet. - Warfarin: possible increase in INR, monitor coagulation parameters. - Methotrexate: reduced renal clearance, watch for toxicity. - Digoxin: slight increase in serum levels, observe for signs of digoxin toxicity.